iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap” [Yahoo! Finance]
iBio, Inc. (IBIO)
NASDAQ:AMEX Investor Relations:
ir.ibioinc.com
Company Research
Source: Yahoo! Finance
design water-soluble, stable engineered epitopes as "personalized baits" aimed at steering antibody discovery toward specific targets and shortening timelines (e.g., IBIO-600 moved from discovery to development candidate in ~7 months and to clinic in ~2 years). Case studies show the platform can break immune tolerance and generate functional binders — examples include latent TGF-beta1 and Activin E immunizations, nanoparticle-displayed epitopes producing robust responses (including llama VHHs), and soluble GPCR surrogates (GIP receptor, CCR8, GPR75) validated by NMR, cryo-EM, and binding assays. iBio sees next-step value in co-engineering epitopes and paratopes to accelerate discovery, while noting generative diffusion models have improved "zero-shot" structural accuracy but still require strong constraints and experimental "babysitting" to avoid non-foldable hallucinations. Interested in iBio, Inc.? Here are five stocks we like better. Legal Issues Behind It, IBIO Stock May B
Show less
Read more
Impact Snapshot
Event Time:
IBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBIO alerts
High impacting iBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBIO
News
- iBio (IBIO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock.MarketBeat
- iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in AustraliaGlobeNewswire
- iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3 [Yahoo! Finance]Yahoo! Finance
- iBio (IBIO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock.MarketBeat
- iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) [Yahoo! Finance]Yahoo! Finance
IBIO
Sec Filings
- 4/8/26 - Form 8-K
- 3/27/26 - Form 4
- 3/23/26 - Form 4
- IBIO's page on the SEC website